AR049284A1 - Compuestos derivados de 1,3-tiazol; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas a la actividad de los ppard - Google Patents
Compuestos derivados de 1,3-tiazol; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas a la actividad de los ppardInfo
- Publication number
- AR049284A1 AR049284A1 ARP050102113A ARP050102113A AR049284A1 AR 049284 A1 AR049284 A1 AR 049284A1 AR P050102113 A ARP050102113 A AR P050102113A AR P050102113 A ARP050102113 A AR P050102113A AR 049284 A1 AR049284 A1 AR 049284A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- substituted
- alkoxy
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/16—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos, composiciones farmacéuticas que comprenden estos compuesto, y métodos para utilizar tales compuestos con el fin de tratar o prevenir enfermedades o desordenes asociados con la actividad de las familias del Receptor Activado por Proliferador de Peroxisoma (PPAR), en particular la actividad de PPARdelta. Reivindicacion 1: Un compuesto de la formula (1) en donde: p es un entero seleccionado de 0 a 3; L2 se selecciona a partir de -XOX-, -XS(O)0-2X- y -XS(O)0-2XO-; en donde X se selecciona independientemente a partir de un enlace y alquileno C1-4; en donde cualquier alquileno de L2 puede estar opcionalmente sustituido por 1 a 3 radicales seleccionados a partir de halogeno, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; R13 se selecciona a partir de halogeno, alquilo c1-6, alcoxilo C1-6, hidroxi-alquilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido por halogeno, arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12, y heterocicloalquilo C3-8; en donde cualquier arilo, heteroarilo, cicloalquilo, y heterocicloalquilo de R13 está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados a partir de halogeno, nitro, ciano, alquilo C1-6, alcoxilo C1-6, hidroxi-alquilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; R14 se selecciona a partir de -XOXC(O)OR17 y -XC(O)OR17; en donde X es un enlace o alquileno C1- 4; y R17 se selecciona a partir de H y alquilo C1-6; R15 y R16 se seleccionan independientemente a partir de -R18 y -YR18; en donde Y se selecciona a partir de alquileno C1-6, alquenileno C2-6, alquinileno C2-6, -C(O)NR17- y -OX-; X es un enlace o alquileno C1-4; R17 se selecciona a partir de H y alquilo C1-6; y R18 se selecciona a partir de cicloalquilo C3-12, hetero-ciclo-alquilo C3-8, arilo C6-10, y hetero-arilo C5-13, o R15 y R16, junto con los átomos con los que están unidos R15 y R16, forman un heteroarilo C5-14 bicíclico o tricíclico fusionado; en donde cualquier arilo, hetero-arilo, cicloalquilo, y hetero-ciclo-alquilo de R18, o la combinacion de R15 y R16, está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados a partir de halogeno, nitro, ciano, alquilo C1-6, alcoxilo C1-6, tioalquilo C1-6, hidroxi-alquilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido por halogeno, ciclo-alquilo C3-12, hetero-ciclo-alquilo C3-8, arilo C6-10, hetero-arilo C5-13, -XS(O)0-2R17, -XS(O)0-2XR19, -XNR17R17, -XNR17S(O)0-2R17, -XNR17C(O)R17, -XC(O)NR17R17, -XNR17C(O)R19, -XC(O)NR17R19, -XC(O)R19, -XNR17XR19, y -XOXR19; en donde cualquier sustituyente de arilo, heteroarilo, cicloalquilo, o heterocicloalquilo está además sustituido opcionalmente con 1 a 3 radicales independientemente a partir de halogeno, nitro, ciano, alquilo C1-6, alcoxilo C1-6, tioalquilo C1-6, hidroxi-alquilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; en donde X es un enlace o alquileno C1-4, R17 se selecciona a partir de H y alquilo C1-4, y R19 se selecciona a partir de cicloalquilo C3-12, heterocicloalquilo C3-8, arilo C6-10, y heteroarilo C5-10, en donde cualquier arilo, heteroarilo, cicloalquilo, o heterocicloalquilo de R19 está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados a partir de halogeno, nitro, ciano, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; y las sales farmacéuticamente aceptables, hidratos, solvatos, isomeros, y profármacos del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57413704P | 2004-05-24 | 2004-05-24 | |
US64898505P | 2005-01-31 | 2005-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049284A1 true AR049284A1 (es) | 2006-07-12 |
Family
ID=35450818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102113A AR049284A1 (es) | 2004-05-24 | 2005-05-23 | Compuestos derivados de 1,3-tiazol; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas a la actividad de los ppard |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070203155A1 (es) |
EP (1) | EP1748993A4 (es) |
JP (1) | JP2008500355A (es) |
AR (1) | AR049284A1 (es) |
AU (1) | AU2005247931B2 (es) |
BR (1) | BRPI0511477A (es) |
CA (1) | CA2563818A1 (es) |
EC (1) | ECSP067021A (es) |
IL (1) | IL179376A0 (es) |
MA (1) | MA28660B1 (es) |
MX (1) | MXPA06013591A (es) |
NO (1) | NO20065984L (es) |
PE (1) | PE20060315A1 (es) |
RU (1) | RU2413723C2 (es) |
TW (1) | TW200612926A (es) |
WO (1) | WO2005116000A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
US20070015839A1 (en) * | 2005-07-14 | 2007-01-18 | Franco Folli | Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome |
PT1907374E (pt) | 2005-07-26 | 2012-11-05 | Glaxo Group Ltd | Derivados de benzilpiperazina úteis para o tratamento de doenças gastrointestinais |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1945620A2 (en) * | 2005-11-07 | 2008-07-23 | Irm Llc | Compounds and compositions as ppar modulators |
KR20080056288A (ko) * | 2005-11-07 | 2008-06-20 | 아이알엠 엘엘씨 | Ppar 조절제로서의 화합물 및 조성물 |
CA2635541A1 (en) * | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
JP5323684B2 (ja) | 2006-05-04 | 2013-10-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多形体 |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
CA2677706A1 (en) * | 2007-02-22 | 2008-08-28 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
JP5544296B2 (ja) | 2007-11-16 | 2014-07-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
ES2553340T3 (es) | 2007-12-12 | 2015-12-07 | Rigel Pharmaceuticals, Inc. | Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos |
AU2012203026B2 (en) * | 2008-03-21 | 2014-06-12 | Novartis Ag | Novel heterocyclic compounds and uses thereof |
US8129394B2 (en) * | 2008-03-21 | 2012-03-06 | Novartis Ag | Heteroaryl-substituted imidazole compounds and uses thereof |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
JP5658138B2 (ja) | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
EP2504002B1 (en) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
EA036404B1 (ru) * | 2015-02-06 | 2020-11-06 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
EP3383389B1 (en) * | 2015-11-30 | 2021-04-28 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as blt1 antagonists |
EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR74148B (es) * | 1980-04-03 | 1984-06-06 | Wyeth John & Brother Ltd | |
IT1248528B (it) * | 1991-06-21 | 1995-01-19 | Pierrel Spa | Derivati di eteri e tioeteri (etero) aromatici aventi attivita` antiiperlipidemica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
JP3197602B2 (ja) * | 1992-02-17 | 2001-08-13 | 久光製薬株式会社 | チアゾール類縁化合物及び皮膚外用剤 |
JPH11147881A (ja) * | 1997-08-21 | 1999-06-02 | Sankyo Co Ltd | ジヒドロベンゾキノン骨格を有する除草性アゾール誘導体 |
EP1067109B1 (en) * | 1998-03-10 | 2009-12-09 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
AU2001277723A1 (en) * | 2000-08-11 | 2002-02-25 | Nippon Chemiphar Co., Ltd. | Ppardelta activators |
US20030170858A1 (en) * | 2001-01-16 | 2003-09-11 | Paul Charifson | Gyrase inhibitors and uses thereof |
EP1371650A4 (en) * | 2001-03-23 | 2005-05-04 | Nippon Chemiphar Co | ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS |
JP2002348281A (ja) * | 2001-03-23 | 2002-12-04 | Takeda Chem Ind Ltd | 5員複素環アルカン酸誘導体 |
EP2314576A1 (en) * | 2003-11-05 | 2011-04-27 | F.Hoffmann-La Roche Ag | Phenyl derivatives as PPAR agonists |
-
2005
- 2005-05-20 PE PE2005000559A patent/PE20060315A1/es not_active Application Discontinuation
- 2005-05-23 TW TW094116635A patent/TW200612926A/zh unknown
- 2005-05-23 AR ARP050102113A patent/AR049284A1/es unknown
- 2005-05-24 EP EP05754130A patent/EP1748993A4/en not_active Withdrawn
- 2005-05-24 RU RU2006145894/04A patent/RU2413723C2/ru not_active IP Right Cessation
- 2005-05-24 MX MXPA06013591A patent/MXPA06013591A/es not_active Application Discontinuation
- 2005-05-24 AU AU2005247931A patent/AU2005247931B2/en not_active Ceased
- 2005-05-24 US US11/597,282 patent/US20070203155A1/en not_active Abandoned
- 2005-05-24 CA CA002563818A patent/CA2563818A1/en not_active Abandoned
- 2005-05-24 BR BRPI0511477-2A patent/BRPI0511477A/pt not_active IP Right Cessation
- 2005-05-24 WO PCT/US2005/018167 patent/WO2005116000A1/en active Application Filing
- 2005-05-24 JP JP2007515255A patent/JP2008500355A/ja active Pending
-
2006
- 2006-11-16 IL IL179376A patent/IL179376A0/en unknown
- 2006-11-22 EC EC2006007021A patent/ECSP067021A/es unknown
- 2006-12-12 MA MA29526A patent/MA28660B1/fr unknown
- 2006-12-22 NO NO20065984A patent/NO20065984L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ECSP067021A (es) | 2006-12-29 |
PE20060315A1 (es) | 2006-05-15 |
EP1748993A4 (en) | 2010-04-28 |
US20070203155A1 (en) | 2007-08-30 |
AU2005247931A1 (en) | 2005-12-08 |
NO20065984L (no) | 2007-02-05 |
MA28660B1 (fr) | 2007-06-01 |
IL179376A0 (en) | 2007-03-08 |
AU2005247931B2 (en) | 2008-10-23 |
RU2413723C2 (ru) | 2011-03-10 |
RU2006145894A (ru) | 2008-06-27 |
BRPI0511477A (pt) | 2007-12-26 |
WO2005116000A1 (en) | 2005-12-08 |
EP1748993A1 (en) | 2007-02-07 |
CA2563818A1 (en) | 2005-12-08 |
JP2008500355A (ja) | 2008-01-10 |
TW200612926A (en) | 2006-05-01 |
MXPA06013591A (es) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049284A1 (es) | Compuestos derivados de 1,3-tiazol; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas a la actividad de los ppard | |
AR049186A1 (es) | Derivados de oxazol como moduladores de ppar | |
PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
AR051997A1 (es) | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos | |
AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
WO2009082268A3 (ru) | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
AR041997A1 (es) | Derivados de oxaxol sustituidos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de la diabetes | |
AR043998A1 (es) | Acidos fenoxiaceticos | |
AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos | |
BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
AR078756A1 (es) | Moduladores alostericos positivos (map) | |
AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
AR066020A1 (es) | Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1. | |
AR043181A1 (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6 | |
AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
AR048501A1 (es) | Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |